Shopping Cart 0
Cart Subtotal
USD 0

DURECT Corp (DRRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company's major products include Alzet, an osmotic pump; and Lactel, a biodegradable polymer. The company's product pipeline comprises DUR-928 indicated for treatment of acute organ injuries and metabolic/lipid disorders; Remoxy, indicated for chronic pain; Posimir, indicated for post-operative pain; Eladur, indicated for post herpetic neuralgia; Oradur, indicated for chronic pain and attention deficit hyperactivity disorder; and Relday, indicated for Schizophrenia and bipolar disorder. Durect's major drug delivery technology platforms include Saber, Cloud, Oradur and Transdur. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in California, the US.

DURECT Corp (DRRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

DURECT Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

DURECT Corp, Medical Devices Deals, 2012 to YTD 2018 10

DURECT Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

DURECT Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Durect Enters into Licensing Agreement with Santen Pharma 12

Licensing Agreements 13

Sandoz Amends Licensing Agreement with DURECT 13

Impax Labs Enters Into Licensing Agreement With Durect For Eladur 14

Otonomy Enters into Licensing Agreement with Durect 16

Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 17

Equity Offering 18

Durect Plans to Raise up to USD175 Million in Public Offering of Securities 18

Durect Raises USD17.3 Million in Public Offering of Shares 19

Durect Files Registration Statement For Public Offering Of Securities For USD 100.9 Million 21

Durect Files Registration Statement For Public Offering Of Common Stock For Up To USD 25 Million 22

Durect Completes Public Offering Of Shares For USD 11.5 Million 23

Durect Completes Public Offering Of Shares For USD 13 Million 24

Asset Transactions 25

Indivior Acquires Certain US Patent Rights from Durect 25

DURECT Corp-Key Competitors 26

DURECT Corp-Key Employees 27

DURECT Corp-Locations And Subsidiaries 28

Head Office 28

Recent Developments 29

Financial Announcements 29

Aug 01, 2018: DURECT announces second quarter 2018 financial results and provides corporate update 29

May 02, 2018: DURECT Reports First Quarter 2018 Financial Results 31

Mar 01, 2018: DURECT Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs 33

Nov 01, 2017: DURECT Announces Third Quarter 2017 Financial Results and Provides Corporate Update 35

Aug 08, 2017: DURECT Announces Second Quarter 2017 Financial Results and Provides Corporate Update 37

May 10, 2017: DURECT Announces First Quarter 2017 Financial Results and Provides Corporate Update 39

Mar 14, 2017: DURECT Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs 41

Corporate Communications 43

Oct 01, 2018: DURECT names Michael H. Arenberg as Chief Financial Officer 43

Oct 01, 2018: DURECT names Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer 44

Sep 20, 2017: DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development 45

Product News 46

09/18/2018: DURECT Announces Methydur sustained release capsules receive marketing authorization for ADHD in Taiwan 46

02/20/2018: DURECT to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC) 47

Clinical Trials 48

Apr 25, 2018: DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis 48

Feb 26, 2018: DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis 49

Aug 08, 2017: ORADUR-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in Taiwan 50

Jun 22, 2017: DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR 51

Apr 24, 2017: DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis at The International Liver Congress 2017 52

Apr 17, 2017: DURECT to Present Clinical Data at the International Liver Congress 2017 53

Jan 30, 2017: DURECT Announces Update on DUR-928 Development Program 54

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

DURECT Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

DURECT Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

DURECT Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

DURECT Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

DURECT Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

DURECT Corp, Deals By Therapy Area, 2012 to YTD 2018 9

DURECT Corp, Medical Devices Deals, 2012 to YTD 2018 10

DURECT Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Durect Enters into Licensing Agreement with Santen Pharma 12

Sandoz Amends Licensing Agreement with DURECT 13

Impax Labs Enters Into Licensing Agreement With Durect For Eladur 14

Otonomy Enters into Licensing Agreement with Durect 16

Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 17

Durect Plans to Raise up to USD175 Million in Public Offering of Securities 18

Durect Raises USD17.3 Million in Public Offering of Shares 19

Durect Files Registration Statement For Public Offering Of Securities For USD 100.9 Million 21

Durect Files Registration Statement For Public Offering Of Common Stock For Up To USD 25 Million 22

Durect Completes Public Offering Of Shares For USD 11.5 Million 23

Durect Completes Public Offering Of Shares For USD 13 Million 24

Indivior Acquires Certain US Patent Rights from Durect 25

DURECT Corp, Key Competitors 26

DURECT Corp, Key Employees 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

DURECT Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company's major products include Alzet, an osmotic pump; and Lactel, a biodegradable polymer. The company's product pipeline comprises DUR-928 indicated for treatment of acute organ injuries and metabolic/lipid disorders; Remoxy, indicated for chronic pain; Posimir, indicated for post-operative pain; Eladur, indicated for post herpetic neuralgia; Oradur, indicated for chronic pain and attention deficit hyperactivity disorder; and Relday, indicated for Schizophrenia and bipolar disorder. Durect's major drug delivery technology platforms include Saber, Cloud, Oradur and Transdur. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in California, the US.

DURECT Corp (DRRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

DURECT Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

DURECT Corp, Medical Devices Deals, 2012 to YTD 2018 10

DURECT Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

DURECT Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Durect Enters into Licensing Agreement with Santen Pharma 12

Licensing Agreements 13

Sandoz Amends Licensing Agreement with DURECT 13

Impax Labs Enters Into Licensing Agreement With Durect For Eladur 14

Otonomy Enters into Licensing Agreement with Durect 16

Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 17

Equity Offering 18

Durect Plans to Raise up to USD175 Million in Public Offering of Securities 18

Durect Raises USD17.3 Million in Public Offering of Shares 19

Durect Files Registration Statement For Public Offering Of Securities For USD 100.9 Million 21

Durect Files Registration Statement For Public Offering Of Common Stock For Up To USD 25 Million 22

Durect Completes Public Offering Of Shares For USD 11.5 Million 23

Durect Completes Public Offering Of Shares For USD 13 Million 24

Asset Transactions 25

Indivior Acquires Certain US Patent Rights from Durect 25

DURECT Corp-Key Competitors 26

DURECT Corp-Key Employees 27

DURECT Corp-Locations And Subsidiaries 28

Head Office 28

Recent Developments 29

Financial Announcements 29

Aug 01, 2018: DURECT announces second quarter 2018 financial results and provides corporate update 29

May 02, 2018: DURECT Reports First Quarter 2018 Financial Results 31

Mar 01, 2018: DURECT Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs 33

Nov 01, 2017: DURECT Announces Third Quarter 2017 Financial Results and Provides Corporate Update 35

Aug 08, 2017: DURECT Announces Second Quarter 2017 Financial Results and Provides Corporate Update 37

May 10, 2017: DURECT Announces First Quarter 2017 Financial Results and Provides Corporate Update 39

Mar 14, 2017: DURECT Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs 41

Corporate Communications 43

Oct 01, 2018: DURECT names Michael H. Arenberg as Chief Financial Officer 43

Oct 01, 2018: DURECT names Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer 44

Sep 20, 2017: DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development 45

Product News 46

09/18/2018: DURECT Announces Methydur sustained release capsules receive marketing authorization for ADHD in Taiwan 46

02/20/2018: DURECT to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC) 47

Clinical Trials 48

Apr 25, 2018: DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis 48

Feb 26, 2018: DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis 49

Aug 08, 2017: ORADUR-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in Taiwan 50

Jun 22, 2017: DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR 51

Apr 24, 2017: DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis at The International Liver Congress 2017 52

Apr 17, 2017: DURECT to Present Clinical Data at the International Liver Congress 2017 53

Jan 30, 2017: DURECT Announces Update on DUR-928 Development Program 54

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

DURECT Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

DURECT Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

DURECT Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

DURECT Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

DURECT Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

DURECT Corp, Deals By Therapy Area, 2012 to YTD 2018 9

DURECT Corp, Medical Devices Deals, 2012 to YTD 2018 10

DURECT Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Durect Enters into Licensing Agreement with Santen Pharma 12

Sandoz Amends Licensing Agreement with DURECT 13

Impax Labs Enters Into Licensing Agreement With Durect For Eladur 14

Otonomy Enters into Licensing Agreement with Durect 16

Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 17

Durect Plans to Raise up to USD175 Million in Public Offering of Securities 18

Durect Raises USD17.3 Million in Public Offering of Shares 19

Durect Files Registration Statement For Public Offering Of Securities For USD 100.9 Million 21

Durect Files Registration Statement For Public Offering Of Common Stock For Up To USD 25 Million 22

Durect Completes Public Offering Of Shares For USD 11.5 Million 23

Durect Completes Public Offering Of Shares For USD 13 Million 24

Indivior Acquires Certain US Patent Rights from Durect 25

DURECT Corp, Key Competitors 26

DURECT Corp, Key Employees 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

DURECT Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.